Investors
Accelerating the development of new therapies and improving the diagnosis and treatment of serious diseases, we deliver value for our investors and partners, as well as those whose lives we touch.
We Deliver at a Global Scale
Benefits for all stakeholders
The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.
Press Releases and Corporate Updates
Latest Press Release
Disclosure of total number of voting rights and number of shares in the capital as of November 30th, 2024
Latest Corporate Update
KOL webinar: The eyonis™ Lung Cancer Screening (LCS) REALITY data – What leading U.S. clinical pulmonology experts are saying
Analyst Coverage
Median Technologies is followed by the analysts listed below.
Any opinions, estimates, forecasts and recommendations regarding Median Technologies made by these analysts are their own. These opinions, estimates, forecasts and recommendations may or may not represent those of Median’s management.
Company
Analyst
Gilbert Dupont
Pierre Alexandre Desir
TP ICAP / Midcap
Claire Deray
Bryan, Garnier & Co
Maria Vara
Portzamparc
Clément Bassat
Financial Agenda
Next financial communication: 2024 half year results on October 24, 2024 after trading.
Regulatory Documents
Latest Financial report
04/25/20242023 FY Financial Report
Download here
LATEST Shareholder meeting
06/19/2024Shareholders’ Ordinary and Extraordinary General Meeting
Other regulated information
Disclosure of Total Number of Voting Rights and Number of Shares in the Capital
Investor Contacts
Median Technologies
Fredrik Braginvestor@mediantechnologies.comSeitosei Actifin
Financial Communications
Ghislaine Gasparettoghislaine.gasparetto@seitosei-actifin.comTel: +33 1 56 88 11 11TP ICAP MIDCAP
Listing Sponsor
Alice Ayméaayme@midcapp.com